AMAALA
1.3.2020 19:54:07 CET | Business Wire | Press release
AMAALA, the ultra-luxury destination located along Saudi Arabia’s northwestern coastline, has announced the appointment of British award-winning architectural design and engineering firm, Foster + Partners. The firm will act as Architectural Advisors of the development.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200301005055/en/
Rooted in the philosophies of art, wellness, and the purity of the Red Sea, AMAALA is set in the Prince Mohammed bin Salman Nature Reserve across three unique communities: Triple Bay, The Island, and The Coastal Development. The trio of communities will represent three different sets of experiences for visitors, with Foster + Partners responsible for innovative and sustainable design solutions across AMAALA’s masterplans and projects.
Chief Executive Officer Nicholas Naples of AMAALA , commented : “AMAALA will represent a singularly unique experience, one which redefines the ultra-luxury experience in its entirety. We are delighted to be partnering with one of the world’s most recognised names in architecture and design to realise our vision. There is a natural synergy with Foster + Partners, whose ongoing commitment towards sustainability and green projects is aligned with our ethos and commitment to being net carbon neutral from day one of operations. Creating a coastal oasis that elevates the role of responsible tourism globally.”
AMAALA seeks to strike an emotional chord with visitors through the creation of transformative experiences, individually curated to guests needs, while the exclusivity of the destination aligns it with those who are connoisseurs of fine living.
Senior Partner Stuart Latham of Foster + Partners, said: “The ambition and scale of the project is striking, and we’re excited to help the Kingdom of Saudi Arabia with its vision for an unforgettable luxury experience which acknowledges the sensitive nature and ecological significance of the site for tourists from across the globe.”
AMAALA is reinventing commonly experienced activities into an all year-round destination based on the beauty and untouched nature of the Red Sea, extending the Mediterranean yachting season from October to December. Through its trio of communities, AMAALA will establish a globally recognised hub for arts and culture with a focus on contemporary art, as well as the most comprehensive, integrated health, wellness and sports offering globally.
- Triple Bay will offer a fully holistic wellness retreat, state-of-the-art diagnostic medical facilities and authentic treatments designed to feature the local environment. Triple Bay will also be home to a fully integrated sports and entertainment community.
- The Coastal Development is set to become the defining hub of contemporary art in the Middle East, playing host to a dynamic programme of exciting events from the global arts and cultural calendar.
- The Island will be the tranquil home of an exclusive art community, set amid an Arabic botanical garden complemented by a collection of sculptural pieces.
Nested in Saudi Arabia’s Vision 2030 plan, the development of AMAALA is being rolled out across three key phases, with completion of the destination ahead of the realisation of Saudi Vision 2030.
*Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20200301005055/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom